Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-338-8 | CAS number: 791-28-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 977
- Report date:
- 1977
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- no ophtalmological examination; no examination of sensory reactivity
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Triphenylphosphine oxide
- EC Number:
- 212-338-8
- EC Name:
- Triphenylphosphine oxide
- Cas Number:
- 791-28-6
- Molecular formula:
- C18H15OP
- IUPAC Name:
- triphenylphosphine oxide
- Details on test material:
- - Name of test material (as cited in study report): Triphenylphosphinoxid
- Purity: pure p.a.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: SPF breeding, WIGA, Sulzfeld
- Age at study initiation (1st application): 42 d
- Weight at study initiation (1st application): males: 144 g, females 120 g
- Housing: 2 or 3 per cage
- Diet: Altromin-R, ALTROGGE, Lage/Lippe, ad libitum
- Water: tap water, ad libitum
- Acclimation period: 7 d
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22+-2
- Humidity (%): 55+-5
- Photoperiod (hrs dark / hrs light): 12:12
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): weekly - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- continuously
Doses / concentrations
- Remarks:
- Doses / Concentrations:
20; 100; 500; 2500 ppm in diet (equivalent 2; 10; 50; 250 mg/kg bw; Diets (ppm) were converted to mg/kg bw by division by factor 10 [Derelanko (2000). Toxicologist's Pocket Handbook. CRC Press])
Basis:
nominal in diet
- No. of animals per sex per dose:
- 30 (10/30 animals were used for the recovery groups)
- Control animals:
- yes, plain diet
- Details on study design:
- Post-exposure period: 42 days (recovery; 10 animals per sex per dose)
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights were recorded weekly
FOOD CONSUMPTION: Yes
-Time schedule: Food consumption was recorded daily
HAEMATOLOGY: Yes
- Time schedule for collection of blood: before the start of the study (prefeeding/acclimatisation period) , after week 4 and week 12 in all animals; after week 6 of the recovery period in all animals of the recovery group
- parameters: hemoglobin, hematocrit, erythrocyte count, mean cell volume, mean cell hemoglobin concentration of single erythrocytes, mean corpuscular hemoglobin concentration, total and differential leucocyte counts, thrombocyte count
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: before the start of the study, during week 6 and during week 13
- Animals fasted: No data
- How many animals: 10 males and 10 females
- parameters: alkaline phosphatise, glutamate pyruvate transaminase, glucose, urea, total protein, total lipid, total bilirubin, sodium, potassium, chloride, calcium, inorganic phosphate , carbon dioxide, creatinine.
URINALYSIS: Yes
- Time schedule for collection of urine after week 3, 7 and 11 in all animals; after week 5 of the recovery period in all animals of the recovery groups
- Metabolism cages used for collection of urine: yes
- parameters: pH, glucose, protein, urobilinogen, sediment - Sacrifice and pathology:
- At the end of the exposure and at the end of the post exposure period, fasted animals were sacrificed and individual necropsies were performed.
Tissues examined included: heart, liver, kidney, spleen, testicles (ovaries), thyroid gland, adrenal glands, pituitary gland, brain, lung, pancreas, stomach, small intestine, large intestine, lymph nodes, skin, eyes with optic nerve, nerves, nasal and faucal mucosa, tongue, cranial bone, salivary glands, skeletal muscles, thymus, trachea, oesophagus, aorta thoracica, prostate gland, uterus, seminal vesicles, epididymis, adipose tissue, tail, left hind leg and sternum.
Following organs were weighed: heart, liver, kidneys, spleen, gonads, thyroid and adrenals (the latter two having
been fixed immediately after dissection). - Statistics:
- Food uptake, body weights & organ weights: ANOVA, t-test
Clinical chemistry & hematology : Nalimov correction followed by t-test
Urinalysis: chi2-test with Yates correction
Results and discussion
Results of examinations
- Details on results:
- 2 mg/kg bw (2 ppm):
No effect was seen.
10 mg/kg bw (100 ppm):
No effect was found concerning clinical parameters.
Hematological and clinicochemical alterations:
From the 8th week of study alkaline phosphatase activity was reduced, returning to normal in the recovery period.
Necropsy:
Reversible effects were seen for the organ weigths of liver and kidney.
Observed fine vacuolar degenerations of the liver were also reversible.
50mg/kg bw (500 ppm):
Clinical parameters:
In females feed consumption and body weight gain were reduced.
Slightly ruffled fur and hyperexcitability were described for both genders.
Hematological and clinicochemical alterations:
Increased protein contents, decreased glucose values, and increased total lipid contents in both genders.
Alkaline phosphatase activity in plasma was reduced at the end of the study, hemoglobin count was reduced in females, thrombocyte count was increased in both genders.
At the end of the recovery period, these values returned to normal.
Necropsy:
All investigated organs in males (liver, kidney, spleen, testes, adrenals), with the exception of the thyroid, showed increased absolute and relative weights.
In females, absolute liver weights were increased; the only increased relative weights were those of liver, too, and kidney.
The organ weight changes were reversible in the recovery period.
In 12/20 males and 7/20 females, degeneration in the hepatic epithelium was seen at the end of the treatment period, which could only be observed in 1/10 males and 1/10 females at the end of the recovery period.
250 mg/kg bw (2500 ppm):
Within the lethal range.
3/30 males and 4/30 females died.
Clinical parameters:
Slightly ruffled fur, nervousness, and partially distended abdomen were described, after 4 weeks of treatment increased aggression was observed.
Towards the end of the study atrophy of the muscles of the hind limbs was detected.
Food consumption and body weight gain were considerably impaired in this group.
Hematological and clinicochemical alterations:
Reduced glucose values, increased lipid values and an increased activity of alkaline phosphatase were described. Hemoglobin contents and hematocrit values were reduced, thrombocyte counts increased.
Necropsy:
The increased weights of liver and adrenals were irreversible.
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- ca. 2 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: equivalent to 20 ppm; no effects observed
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 10 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: equivalent to 100 ppm; reversible effects (reduced alkaline phosphatase activity, changed liver and kidney weight, fine vascular degeneration in the liver) were considered as not adverse
- Dose descriptor:
- LOAEL
- Effect level:
- ca. 50 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.